Tetra Bio-Pharma Inc.

OTCPK:TBPM.Q Stock Report

Market Cap: US$515.0

Tetra Bio-Pharma Past Earnings Performance

Past criteria checks 0/6

No hay datos suficientes sobre los resultados de Tetra Bio-Pharma en los últimos años.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth raten/a
Return on equityn/a
Net Marginn/a
Last Earnings Update31 Aug 2022

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown
Beta

How Tetra Bio-Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:TBPM.Q Revenue, expenses and earnings (CAD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Aug 220-3985
31 May 220-4196
28 Feb 220-45107
30 Nov 210-521212
31 Aug 210-291214
31 May 210-281015
28 Feb 210-251014
30 Nov 200-21912
31 Aug 200-1798
31 May 200-1596
29 Feb 200-1486
30 Nov 190-1376
31 Aug 190-1478
31 May 190-1077
28 Feb 190-1077
30 Nov 180-866
31 Aug 180-563
31 May 180-863
28 Feb 180-753
30 Nov 170-652
31 Aug 170-533
31 May 170-422
28 Feb 170-211
30 Nov 160-110
31 Aug 160-110
31 May 160000
29 Feb 160000
30 Nov 150-100
31 Aug 150010

Beneficios de calidad: Datos insuficientes para determinar si TBPM.Q tiene ganancias de alta calidad.

Creciente margen de beneficios: No hay datos suficientes para determinar si los márgenes de beneficio de TBPM.Q han mejorado en el último año.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Tendencia de beneficios: No hay datos suficientes para determinar si la tasa de crecimiento interanual de los beneficios de TBPM.Q ha sido positiva en los últimos 5 años.

Acelerando crecimiento: No hay datos suficientes para comparar el crecimiento de los beneficios del último año de TBPM.Q con su media de 5 años.

Beneficios vs. Industria: Datos insuficientes para determinar si el crecimiento de los beneficios de TBPM.Q en el último año superó la media del sector Pharmaceuticals.


Return on Equity

Alto ROE: TBPM.Q tiene un Rendimiento de los fondos propios negativo (0%), ya que actualmente no es rentable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.